Astellas

Blending human knowhow, artificial intelligence aids drug discovery

02-Aug-2022 By Jenni Spinner

A leader from pharmaceutical firm Astellas discusses how the company has put to use a discovery platform that combines human expertise, AI, and robotics.

People on the Move: October 2020

07-Oct-2020 By Jenni Spinner

The latest news on pharmaceutical industry hires, promotions, acquisitions and other events includes Medable, Eversana, Parexel, Astellas and more.

Astellas taps into Pandion’s platform for bispecifics development

05-Nov-2019 By Vassia Barba

Astellas and Pandion join forces to develop treatments for autoimmune pancreatic diseases using the latter’s modular immune effector.

Astellas licenses Frequency’s lead drug for $625m

22-Jul-2019 By Ben Hargreaves

Astellas agrees a deal for the ex-US rights of Frequency’s lead drug candidate, FX-322, after the latter company posted positive results in a Phase I/II trial.

NEWS IN BRIEF

Otsuka enters the API business after Astellas asset acquisition

10-Jun-2019 By Ben Hargreaves

Otsuka acquires Astellas’ Cefixime business, which means it will supply the API to overseas licensees and thereby enter the API business.